VitriVax
Boulder
About VitriVax
VitriVax is a formulation technology company that develops solutions to enhance the global distribution and effectiveness of human vaccines. The company's core technology, Atomic Layering Thermostable Antigen and Adjuvant platform, addresses two major logistical barriers in vaccination. This platform eliminates the need for a cold chain by making vaccines thermostable, allowing them to be stored and transported at ambient temperatures up to 70°C for months.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $35.8M
- Funding stage: Early Stage Venture
- Last round: Series B (Oct 2025)
- Website: vitrivaxbio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Medical Device, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vitrivax-26615 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.